시장보고서

상품코드

1735608

파상풍 톡소이드 백신 시장 : 백신 유형별, 연령층별, 최종사용자별, 지역별(2026-2032년)

Tetanus Toxoid Vaccine Market By Vaccine Type, By Age Group, By End-User, And Region for 2026-2032

발행일: 2025년 05월 | 리서치사:

Verified Market Research | 페이지 정보: 영문 202 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파상풍 톡소이드 백신 시장 평가(2026-2032년)

파상풍 톡소이드 백신 시장은 예방적 의료 조치에 대한 인식이 높아지고 전 세계적으로 파상풍 감염률이 증가함에 따라 파상풍 톡소이드 백신 시장은 2024년 51억 달러에서 2032년까지 예측 기간 동안 80억 4,000만 달러의 가치에 도달할 것으로 예상됩니다.

예방접종 시스템을 개선하기 위한 정부의 조치와 파상풍 백신 접종을 정기 예방접종 일정에 포함시키는 것이 시장 확대의 원동력이 되고 있습니다. 이로 인해 시장은 2026년부터 2032년까지 연평균 5.85%의 CAGR로 성장할 것으로 예상됩니다.

파상풍 톡소이드 백신 시장 정의/개요

파상풍 톡소이드 백신은 클로스트리듐 테타니(Clostridium tetani)에 의한 심각한 세균 감염인 파상풍을 예방하는 치료제입니다. 이 백신 접종은 면역 체계를 자극하여 파상풍 독소에 대한 항체를 생성하여 향후 감염에 대한 면역력을 제공합니다. 파상풍 톡소이드 예방접종은 주로 주사를 통해 이루어지며, 일반적인 어린이 예방접종 일정에 자주 포함되어 있습니다.

또한, 평생 동안 면역력을 유지하기 위해 부스터 접종을 실시합니다. 이 예방접종은 파상풍을 예방하는 데 매우 중요합니다. 파상풍은 심한 근육 경련을 특징으로 하는 질병으로 오염된 상처나 부상으로 인해 발생하며, 경우에 따라서는 치명적인 결과를 초래할 수 있습니다.

파상풍 톡소이드 백신의 수요를 촉진하는 주요 요인은 무엇인가?

파상풍은 특히 백신 접종률이 낮고 클로스트리듐 테타니(Clostridium tetani) 균에 노출될 기회가 많은 지역(예 : 농작업이나 불충분한 위생 환경)에서 전 세계 많은 지역에서 건강 문제로 대두되고 있습니다. 전 세계적으로 파상풍이 계속 재발함에 따라 파상풍 톡소이드 예방접종에 대한 수요가 증가하고 있습니다.

세계보건기구(WHO)와 유니세프(UNICEF)와 같은 국제보건기구는 표준 예방접종 요법과 임산부 및 신생아 파상풍 퇴치 활동의 일환으로 파상풍 예방접종을 적극 장려하고 있습니다. 이러한 이니셔티브는 임산부 및 어린이와 같은 특정 집단에서 높은 접종률을 달성하는 것을 목표로 하기 때문에 파상풍 톡소이드 백신에 대한 접종 수요가 크게 증가하고 있습니다.

또한, 백신 기술 및 제조 기술의 발전으로 보다 효과적이고 안전하며 투여가 용이한 파상풍 톡소이드 백신이 개발되고 있습니다. 파상풍을 포함한 많은 질병을 예방하는 혼합 백신은 그 간편함과 효과로 인해 인기가 높아지고 있습니다. 이러한 기술 혁신은 예방접종 프로그램의 효과를 향상시키고, 의료 전문가와 환자 모두에게 호소력을 높여 시장을 확대할 수 있는 잠재력을 가지고 있습니다.

파상풍 톡소이드 백신의 성장을 가로막는 과제는 무엇인가?

많은 중저소득 국가에서는 파상풍 백신에 대한 접근이 제한되어 있습니다. 이는 열악한 보관 시설, 콜드체인 요구 사항, 유통망과 같은 물류 문제 때문입니다. 이러한 문제는 의료 인프라가 열악한 지방이나 고립된 지역에서는 더욱 심각합니다. 백신이 가장 필요한 곳에 백신을 공급할 수 있도록 하는 것은 파상풍 예방을 위한 공중보건 노력에 큰 도전이 되고 있으며, 시장 확대를 제한하고 있습니다.

또한, 파상풍 톡소이드 백신은 제조, 유통 및 투여에 많은 투자가 필요합니다. 많은 국가, 특히 의료 예산이 적은 국가에서는 예방접종 프로그램을 유지 및 확대할 수 있는 충분한 자금을 확보하는 데 어려움을 겪고 있습니다.

또한, 경제가 불안정해지거나 자금 조달의 우선순위가 바뀌면 예방접종률이 떨어집니다. 국제 원조와 자금 조달 방법은 중요하지만, 세계 보건의 목표와 경제 상황에 따라 달라질 수 있습니다.

The Tetanus Toxoid Vaccine Market is primarily driven by increased awareness of preventative healthcare measures, as well as rising tetanus infection rates worldwide. According to the analyst from Verified Market Research, the Tetanus Toxoid Vaccine Market is estimated to reach a valuation of USD 8.04 Billion over the forecast period 2032, subjugating around USD 5.1 Billion in 2024.

Government measures to improve immunization systems, as well as the incorporation of tetanus vaccination into normal immunization schedules, are driving market expansion. This enables the market to grow at a CAGR of 5.85% from 2026-2032.

Tetanus Toxoid Vaccine Market: Definition/ Overview

Tetanus toxoid vaccine is a medicinal treatment that prevents tetanus, a severe bacterial infection caused by Clostridium tetani. This vaccination stimulates the immune system to develop antibodies against the tetanus toxin, providing immunity against future infections. Tetanus toxoid vaccinations are primarily administered by injection and are frequently included in normal children's immunization schedules.

Furthermore, people receive booster doses to maintain immunity throughout their lives. The vaccination is critical for preventing tetanus, a disease characterized by severe muscle spasms and possibly fatal consequences caused by contaminated wounds or injuries.

What are the Key Drivers that Foster the Demand for Tetanus Toxoid Vaccines?

Tetanus is a health concern in many parts of the world, particularly in regions with low vaccination coverage and people who are more exposed to the bacteria Clostridium tetani (for example, through agricultural work or inadequate sanitation). The continual recurrence of tetanus cases around the world pushes up demand for tetanus toxoid vaccinations, which are the principal way of disease prevention.

Governments and international health organizations, such as the World Health Organization (WHO) and UNICEF, aggressively encourage tetanus immunization as part of standard vaccination regimens and maternal and neonatal tetanus elimination initiatives. These initiatives considerably raise demand for tetanus toxoid vaccinations since they aim to attain high vaccination rates in specific populations such as pregnant women and children.

Furthermore, advances in vaccine technology and production techniques have resulted in the creation of tetanus toxoid vaccines that are more effective, safer, and easier to administer. Combination vaccines that protect against numerous illnesses, including tetanus, are becoming more popular due to their simplicity and efficacy. Such innovations have the potential to extend the market by improving immunization programs' effectiveness and appeal to both healthcare professionals and recipients.

What are the Challenges Hindering the Growth of the Tetanus Toxoid Vaccines?

Many low- and middle-income nations have limited access to tetanus vaccines because of logistical challenges such as poor storage facilities, cold chain requirements, and distribution networks. These problems are exacerbated in rural or isolated places, where healthcare infrastructure is frequently poor. Ensuring that vaccines are available where they are most needed is a big challenge for public health efforts to prevent tetanus, limiting market expansion.

Furthermore, tetanus toxoid vaccines require significant investment to manufacture, distribute, and administer. Many countries, particularly those with low healthcare budgets, struggle to provide enough cash to maintain or grow immunization programs.

Also, economic instability or shifts in financing priorities lead to a decrease in immunization coverage. International aid and financing methods are important, but they are influenced by global health goals and economic situations.

Category-Wise Acumens

What Factors Contribute to the Market Growth of Diphtheria, Tetanus, and Pertussis Vaccines?

According to VMR analysis, the diphtheria, tetanus, and pertussis (DTaP) segment is estimated to exhibit the highest growth during the forecast period. DTaP vaccines are a cornerstone of pediatric immunization programs around the world because they effectively protect against three deadly diseases: diphtheria, tetanus, and pertussis. Many nations incorporate DTaP into their national immunization schedules for children, advising multiple doses to provide long-term immunity. This widespread and habitual use creates a strong demand for vaccines.

The global increase in pertussis (whooping cough) infections has highlighted the need for immunization. The DTaP vaccination protects against pertussis in addition to tetanus and diphtheria, making it particularly useful in attempts to control outbreaks and preserve public health. The rise in pertussis infections, particularly in nations with previously low incidence rates, has raised attention on immunization, driving up demand for DTaP vaccines.

Furthermore, the recommendation for pregnant women to obtain the Tdap vaccine (a variation of DTaP for adolescents and adults) to protect their newborns from pertussis before they reach the age to be vaccinated has also contributed to the segment's dominance. This method, known as "cocooning," seeks to surround infants with family members who have been vaccinated against pertussis, lowering the infant's chance of infection. While Tdap is a related but distinct formulation targeted for older children and adults, its usage supplements the larger strategy of employing DTaP in childhood immunization, strengthening the overall demand for vaccines that protect against tetanus, diphtheria, and pertussis.

What are the Key Driving Forces Leading to the Dominance of the Pediatric Age Group?

The pediatric segment is estimated to dominate the Tetanus Toxoid Vaccine Market during the forecast period. Tetanus vaccines are included in the children's immunization schedule all around the world. Children should get numerous doses of the vaccine (typically coupled with diphtheria and pertussis vaccines as DTP/DTaP) beginning in infancy to develop and maintain immunity. This regular inclusion in national immunization programs maintains a steady demand for the vaccine among the pediatric population.

International and national health organizations promote high vaccination rates among youngsters to prevent epidemics of vaccine-preventable illnesses such as tetanus. The emphasis on children stems from their increased susceptibility to infectious diseases and the long-term benefits of early immunization. Efforts to obtain and maintain high coverage rates in this segment have a substantial impact on the pediatric segment's market dominance.

Furthermore, many countries demand proof of immunization, including tetanus toxoid, for school enrollment. This regulatory strategy ensures that the vast majority of the pediatric population is immunized, which contributes to the segment's significant market share. Such initiatives not only benefit public health but also create ongoing demand for pediatric immunizations.

Country/Region-wise Acumens

What Drivers Contribute to the Sustained Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the Tetanus Toxoid Vaccine Market during the forecast period. North America, particularly the United States and Canada, benefits from a strong healthcare system. This includes easy access to healthcare services, a robust network of hospitals and clinics, and comprehensive immunization programs. Such infrastructure enables efficient vaccine distribution and administration, resulting in high immunization coverage rates. The region's cold chain storage and distribution capabilities are also crucial to ensuring vaccine efficacy from production to administration.

Furthermore, both the United States and Canada devote large money to public health initiatives, including immunization programs. These contributions support not only vaccine purchases but also public health programs aimed at increasing vaccination knowledge and uptake, particularly tetanus toxoid vaccines. Government and commercial insurance coverage for vaccinations helps to increase immunization rates by lowering people's out-of-pocket costs.

What are the Factors Leading to Significant Share in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. Many Asia Pacific countries are experiencing strong economic expansion, which has resulted in greater healthcare spending and major infrastructure upgrades. Governments are investing more in healthcare facilities, vaccine procurement, and cold chain logistics, boosting the region's ability to carry out widespread immunization programs. This finding promotes increased immunization rates and increases demand for tetanus toxoid vaccines.

Furthermore, the Asia Pacific region is home to some of the world's most populated countries, including China and India. With a huge number of newborns and children requiring vaccination as part of standard immunization schedules, there is a high demand for tetanus toxoid vaccines. Furthermore, attempts to enhance maternal health lead to increased immunization among women of reproductive age, which expands the market.

Competitive Landscape

The competitive landscape of the Tetanus Toxoid Vaccine Market is distinguished by the presence of multiple firms working to improve vaccine accessibility, efficacy, and safety. Also, advances in vaccination technology, such as the creation of new adjuvants or combination vaccines, help to increase competition by providing differentiated products.

Some of the prominent players operating in the Tetanus Toxoid Vaccine Market include:

GlaxoSmithKline, Sanofi Pasteur, Merck & Co., Serum Institute of India, Bharat Biotech International Limited, Walvax Biotechnology Co., Wuhan Institute of Biological Products Co., China National Biotec Group Co., Evans Vaccines, Biological E. Limited, CanSino Biologics Inc., Abbott Laboratories, Hoffmann-La Roche Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, CSL Limited, Mylan N.V., Novartis International AG

Latest Developments

In March 2024, Sanofi Pasteur established a collaboration with UNICEF to enhance childhood immunization access in Africa.
In March 2024, Pfizer Inc. published encouraging results from a late-stage clinical trial for a novel respiratory syncytial virus (RSV) vaccine.
In February 2024, The Serum Institute of India reported great financial performance due to increased demand for several vaccines, notably tetanus toxoid vaccines.

1 INTRODUCTION OF GLOBAL TETANUS TOXOID VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL TETANUS TOXOID VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL TETANUS TOXOID VACCINE MARKET, BY VACCINE TYPE

5.1 Overview
5.2 Tetanus Toxoid (TT)
5.3 Diphtheria and Tetanus (DT)
5.4 Tetanus and Diphtheria (Td)
5.5 Diphtheria, Tetanus, and Pertussis (DTaP)
5.6 Tetanus, Diphtheria, and Pertussis (Tdap)
5.7 Pentavalent
5.8 Hexavalent
5.9 Others

6 GLOBAL TETANUS TOXOID VACCINE MARKET, BY AGE GROUP

6.1 Overview
6.2 Pediatric
6.3 Adult

7 GLOBAL TETANUS TOXOID VACCINE MARKET, BY END-USER

7.1 Overview
7.2 Hospitals and Clinics
7.3 Government Organizations
7.4 Others

8 GLOBAL TETANUS TOXOID VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Middle East and Africa
- 8.5.2 Latin America

9 GLOBAL TETANUS TOXOID VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GlaxoSmithKline
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Sanofi Pasteur
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Merck & Co.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Serum Institute of India
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Bharat Biotech International Limited
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Walvax Biotechnology Co.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Wuhan Institute of Biological Products Co.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 China National Biotec Group Co.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Evans Vaccines
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Biological E. Limited
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

파상풍 톡소이드 백신 시장 : 백신 유형별, 연령층별, 최종사용자별, 지역별(2026-2032년)

Tetanus Toxoid Vaccine Market By Vaccine Type, By Age Group, By End-User, And Region for 2026-2032

파상풍 톡소이드 백신 시장 평가(2026-2032년)

파상풍 톡소이드 백신의 수요를 촉진하는 주요 요인은 무엇인가?

파상풍 톡소이드 백신의 성장을 가로막는 과제는 무엇인가?

목차

제1장 파상풍 톡소이드 백신 세계 시장, 소개

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH 조사 방법

제4장 파상풍 톡소이드 백신 세계 시장, 전망

제5장 파상풍 톡소이드 백신 세계 시장 : 백신 유형별

제6장 파상풍 톡소이드 백신 세계 시장 : 연령층별

제7장 파상풍 톡소이드 백신 세계 시장 : 최종사용자별

제8장 파상풍 톡소이드 백신 세계 시장 : 지역별

제9장 파상풍 톡소이드 백신 세계 시장 경쟁 상황

제10장 기업 개요

제11장 주요 발전

제12장 부록

Tetanus Toxoid Vaccine Market Valuation - 2026-2032